Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Belotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belotecan SCHEMBL18983 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL29378860 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL7869454 | 0.99 | TOP1 (0.78) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL31499426 | 0.99 | TOP1 (0.78) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL1651143 | 0.98 | TOP1 (0.76) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL2462051 | 0.92 | TOP1 (0.76) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL22843978 | 0.91 | TOP1 (0.82) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL25845670 | 0.91 | TOP1 (0.64) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL31726483 | 0.90 | TOP1 (0.72) | TOP1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5936616 | 0.90 | TOP1 (0.82) | TOP1MEN1KMT2AALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019189419-A1 | ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | claimed |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-20250381289-A1 | EGFR AND C-MET BISPECIFIC BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2025-12-18 | — | — | US | disclosed |
| US-20250296992-A1 | SLITRK6 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-25 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025149661-A1 | SLITRK6 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB A/S (DK) | 2025-07-17 | — | — | WO | disclosed |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-10 | — | — | US | disclosed |
| US-20250066490-A1 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-02-27 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| WO-2024092067-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4326768-A1 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117279664-A | FOLR1 binding agents, conjugates thereof, and methods of use thereof | 普方生物制药美国公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2022226317-A1 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2020156189-A1 | CAMPTOTHECIN DERIVATIVE AND WATER-SOLUBLE PRODRUG THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD, AND USE | 四川科伦博泰生物医药股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| WO-2019189419-A1 | ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381289-A1 | EGFR AND C-MET BISPECIFIC BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | MET, EGFR, ERBB2 | TOP1 4191/4885MEN1 125/4885KMT2A 1404/4885 |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | TOP1 652/4885MEN1 2485/4885KMT2A 2244/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | TOP1 1057/4885MEN1 3457/4885KMT2A 2327/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TOP1 146/4885MEN1 1967/4885KMT2A 2447/4885 |
| US-20250066490-A1 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | CD74, CD2BP2, CD2 | TOP1 2472/4885MEN1 1175/4885KMT2A 2482/4885 |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | PTK2B, PTK2, LTK | TOP1 2166/4885MEN1 1588/4885KMT2A 1793/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885MEN1 2250/4885KMT2A 2014/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TOP1 146/4885MEN1 1967/4885KMT2A 2447/4885 |
| US-20250296992-A1 | SLITRK6 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | CD2BP2, LY6K, UACA | TOP1 3237/4885MEN1 556/4885KMT2A 3467/4885 |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | MGAT3, GALE, GPI | TOP1 100/4885MEN1 3411/4885KMT2A 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.